Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treating Drug-Resistant Childhood Schizophrenia

This study has been completed.
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by:
Northwell Health
ClinicalTrials.gov Identifier:
NCT00048828
First received: November 8, 2002
Last updated: July 1, 2013
Last verified: July 2013
  Purpose
This study will compare clozapine and olanzapine (Zyprexa®) for the treatment of children and adolescents who have failed standard antipsychotic treatment for schizophrenia.

Condition Intervention Phase
Schizophrenia
Drug: Olanzapine
Drug: Clozapine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treating Refractory Childhood Schizophrenia

Resource links provided by NLM:


Further study details as provided by Northwell Health:

Primary Outcome Measures:
  • Psychotic, manic, aggressive, and depressive symptoms [ Time Frame: Measured over 12 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 41
Study Start Date: October 2001
Study Completion Date: June 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Olanzapine
Participants will receive olanzapine for 12 weeks.
Active Comparator: 2 Drug: Clozapine
Participants will receive 12 weeks of clozapine.

Detailed Description:

Schizophrenia is a devastating illness regardless of the age at which it presents. When this disorder occurs in childhood or adolescence, the consequences in terms of functional impairment, loss of developmental opportunities, and family and societal burden are particularly dramatic.

Evidence supports the improved efficacy and/or side effect profile of atypical antipsychotic medication in adults. Thus, it is essential to examine whether the potential benefits of these agents can be extended to children, particularly children who have failed standard treatment.

Patients are randomly assigned to receive either clozapine or olanzapine daily for 12 weeks. Patients meet with the study team once a week to discuss progress and record side effects. Three parent meetings take place during the study. During these meetings, questions are discussed and support and education about schizophrenia are given to parents. Various scales to measure psychotic, manic, aggressive, and depressive symptoms are used to assess patients.

  Eligibility

Ages Eligible for Study:   10 Years to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • DSM-IV criteria for treatment-refractory schizophrenia or schizoaffective disorder
  • Willingness to use an acceptable form of birth control, if applicable

Exclusion Criteria:

  • Neurological or medical disorders that would contraindicate treatment with clozapine or olanzapine
  • IQ less than 70
  • DSM-IV criteria for substance (other than caffeine or nicotine) related disorder
  • Failure of an adequate trial of olanzapine or clozapine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00048828

Locations
United States, New York
Bronx Children's Psychiatric Center
Bronx, New York, United States, 10461
Sagamore Children's Psychiatric Center
Dix Hills, New York, United States, 11746
Long Island Jewish Medical Center
Glen Oaks, New York, United States, 11004
Sponsors and Collaborators
Northwell Health
National Institute of Mental Health (NIMH)
Investigators
Principal Investigator: Christoph U. Correll, MD The Zucker Hillside Hospital
  More Information

Responsible Party: Christoph U. Correll, MD, The Zucker Hillside Hospital
ClinicalTrials.gov Identifier: NCT00048828     History of Changes
Other Study ID Numbers: R01MH060229  DSIR 84-CTM 
Study First Received: November 8, 2002
Last Updated: July 1, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia, Childhood
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Neurodevelopmental Disorders
Olanzapine
Clozapine
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Serotonin Antagonists
GABA Antagonists
GABA Agents

ClinicalTrials.gov processed this record on December 05, 2016